INTRODUCTION AND OBJECTIVES:
The use of intravesical chemotherapy (IC) immediately following transurethral resection of bladder tumor (TURBT) for low grade (LG) non muscle invasive bladder cancer (NMIBC) has been well demonstrated to reduce local recurrence and is supported by current guidelines. We sought to demonstrate patterns of uptake for this practice as well as its impact on outcomes at a population level as an initial step in developing quality improvement initiates in NMIBC.
METHODS: Incident cases of LG Ta or T1 NMIBC diagnosed between 2005 and 2012 were identified from the California Cancer Registry and linked to hospital records of the Office of Statewide Health Planning and Development. Tumor, patient, and hospital characteristics were included in the analysis. We determined rates of IC utilization following TURBT in patients with LG Ta or T1 NMIBC. Multivariable logistic regression models were utilized to determine predictors of IC utilization. Cumulative incidence functions and Cox Proportional Hazards (PH) models were used to determine predictors of recurrence-free survival (RFS), bladder cancer-specific survival (CSS), and overall survival (OS) with utilization of IC as the primary effector variable.
RESULTS: The final cohort consisted of 10,031 patients with LG NMIBC diagnosed in California between 2005 and 2012, with initial TURBT 45 days from diagnosis. The overall rate of IC utilization was 5.1%, but demonstrated an increase from 1. 7% (2005-2006) to 9.6% (2011) (2012) . On multivariable logistic regression analysis, variables associated with increased odds of immediate IC instillation included more recent year of diagnosis (OR 1.74, CI 1.60-1.90 for 2 year increments). Factors associated with lower odds of receiving IC included Hispanic race (OR 0.62, and Asian/Pacific Islander race (OR 0.58, CI 0.37-0.91). The cumulative incidence of recurrence at 24 months for patients who received IC was 25.2% compared to 30.2% among those that did not receive IC. On multivariable Cox PH analysis, use of IC was significantly associated with an 18% improvement in RFS (HR 0.82, CI 0.70-0.97).
CONCLUSIONS: Utilization of IC for LG NMIBC remains dismally low in routine practice, with less than 10% of patients receiving this standard of care even in more recent years. Poor utilization of this practice is associated with increased rates of recurrence. Strategies utilizing robust implementation of scientific methods should be studied as a means to overcome a major shortcoming in the quality of care provided to patients with LG NMIBC.
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PD19-05 THE BENEFIT OF CONTINUOUS SALINE BLADDER IRRIGATION AFTER TRANSURETHRAL RESECTION IN HIGH GRADE NON-MUSCULAR INVASIVE BLADDER CANCER -A SINGLE CENTER RANDOMIZED PROSPECTIVE STUDY
Takehisa Onishi*, Takuji Shibahara, Masahiko Nishii, Masaki Yoshikawa, Tadashi Yabana, Ise, Japan; Katunori Utida, Tsu, Japan INTRODUCTION AND OBJECTIVES: We have reported the efficacy and safety of continuous saline bladder irrigation (CSBI) after transurethral resection of bladder tumor (TURBT) in low grade nonmuscle invasive bladder cancer (NMIBC) (Onishi T et al. AUA 2016 Annual Meeting, BJU Int, 2016 . The aim of this study was to evaluate the efficacy and safety of CSBI after TURBT in patients with high grade NMIBC.
METHODS: In this prospective randomized study, 226 patients with presumed primary NMIBC eligible for TURBT were enrolled. Patients were randomly allocated to receive CSBI (2,000 ml/h for first 1 hour, then 1,000 ml/h for 2 hours, and then 500 ml/h for 15 hours) or a single immediate instillation of mitomycin C (MMC) after TURBT. The patients with high grade NMIBC were subjected to analyses. Primary end point is recurrence-free survival, and secondary end points were progression-free survival and adverse events.
RESULTS: A total of 147 patients (75 in CSBI group and 72 in MMC group) remained for analysis after exclusion criteria had been applied. The median follow-up period was 36 months. No significant differences in patients' characteristics were observed between the groups. The 5-year recurrence-free rates for CSBI and MMC were 60.5% (95% confidence interval [CI]: 0.48-0.70) and 67.2% (95% CI: 0.54-0.77), respectively. Kaplan-Meire analysis of recurrence-free survival did not show any significant differences between the groups (log rank test: P¼0.56). Furthermore, there were no significant differences between the groups in terms of tumor progression rate and the median time to first recurrence. The incidence of adverse events was significantly lower in CSBI group (8.0% vs 34.7%, P<0.001).
CONCLUSIONS: The results show that CSBI after TURBT may be a treatment option even for patients with high grade NMIBC in terms of its prophylactic effect and safety.
